Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine

被引:325
作者
Kaplan, SL
Mason, EO
Wald, ER
Schutze, GE
Bradley, JS
Tan, TQ
Hoffman, JA
Givner, LB
Yogev, R
Barson, WJ
机构
[1] Baylor Coll Med, Pediat Infect Dis Sect, Houston, TX 77030 USA
[2] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA
[3] Univ Arkansas Med Sci, Little Rock, AR 72205 USA
[4] Childrens Hosp San Diego, San Diego, CA USA
[5] Northwestern Univ, Sch Med, Chicago, IL USA
[6] Univ So Calif, Sch Med, Los Angeles, CA USA
[7] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA
[8] Ohio State Univ, Coll Med & Publ Hlth, Columbus, OH 43210 USA
关键词
Streptococcus pneumoniae; conjugate vaccine; surveillance;
D O I
10.1542/peds.113.3.443
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective. To monitor clinical and microbiologic features including antimicrobial susceptibility and serogroup distribution of invasive infections caused by Streptococcus pneumoniae among children before and after the introduction of routine administration of the 7-valent pneumococcal conjugate vaccine (PCV7). Design. A 9-year ( January 1, 1994 through December 31, 2002) prospective surveillance study of all invasive pneumococcal infections in children. Patients. Infants and children cared for at 8 children's hospitals in the United States with culture-proven invasive infections caused by S pneumoniae. Results. When compared with the mean of the years 1994 to 2000, the annual number of invasive pneumococcal infections for children less than or equal to 24 months of age declined 58% in 2001 and 66% in 2002. If only the serogroups in the PCV7 are considered, the number of cases in children less than or equal to 24 months old declined 63% and 77% in 2001 and 2002, respectively. The greatest decrease was observed for serogroup-14 isolates. The number of isolates in nonvaccine serogroups increased 28% in 2001 and 66% in 2002 for children less than or equal to 24 months old. Nonvaccine serogroup-15 and - 33 isolates had the greatest increase in number. The proportion of all isolates nonsusceptible to penicillin increased yearly from 1994 to 2000, reached a plateau in 2001 at 45%, and declined to 33% in 2002. Decrease in nonsusceptibility to penicillin occurred entirely in the isolates with penicillin minimum inhibitory concentration greater than or equal to 2 mug/mL. Nonsusceptibility to penicillin increased slightly among nonvaccine-serotype isolates. Most infections after at least 2 doses of PCV7 were caused by nonvaccine-serotype isolates. Conclusions. Since the introduction of the PCV7, the number of invasive pneumococcal infections caused by vaccine-serogroup isolates among 8 US children's hospitals has decreased > 75% among children less than or equal to 24 months old. In addition, penicillin resistance decreased in 2002 for the first time since our surveillance began in 1993 1994. However, we have noted that replacement may be developing with serogroups 15 and 33. Furthermore, penicillin resistance seems to be increasing among nonvaccine serogroups. Surveillance must be continued to detect the emergence of changes in the distribution of serotypes as well as antibiotic susceptibility.
引用
收藏
页码:443 / 449
页数:7
相关论文
共 17 条
  • [1] Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
    Black, S
    Shinefield, H
    Fireman, B
    Lewis, E
    Ray, P
    Hansen, JR
    Elvin, L
    Ensor, KM
    Hackell, J
    Siber, G
    Malinoski, F
    Madore, D
    Chang, I
    Kohberger, R
    Watson, W
    Austrian, R
    Edwards, K
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (03) : 187 - 195
  • [2] Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia
    Black, SB
    Shinefield, HR
    Ling, S
    Hansen, J
    Fireman, B
    Spring, D
    Noyes, J
    Lewis, E
    Ray, P
    Lee, J
    Hackell, J
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2002, 21 (09) : 810 - 815
  • [3] Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine
    Black, SB
    Shinefield, HR
    Hansen, J
    Elvin, L
    Laufer, D
    Malinoski, F
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2001, 20 (12) : 1105 - 1107
  • [4] Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers
    Dagan, R
    Givon-Lavi, N
    Zamir, O
    Sikuler-Cohen, M
    Guy, L
    Janco, J
    Yagupsky, P
    Fraser, D
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (07) : 927 - 936
  • [5] Efficacy of a pneumococcal conjugate vaccine against acute otitis media
    Eskola, J
    Kilpi, T
    Palmu, A
    Jokinen, J
    Haapakoski, J
    Herva, E
    Takala, A
    Käyhty, H
    Karma, P
    Kohberger, R
    Siber, G
    Mäkela, PH
    Lockhart, S
    Ecrola, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (06) : 403 - 409
  • [6] Hsu KK, 2003, PEDIATR RES, V53, p308A
  • [7] HSU KK, 2002, 42 INT C ANT AG CHEM
  • [8] Three-year multicenter surveillance of systemic pneumococcal infections in children
    Kaplan, SL
    Mason, EO
    Barson, WJ
    Wald, ER
    Arditi, M
    Tan, TQ
    Schutze, GE
    Bradley, JS
    Givner, LB
    Kim, KS
    Yogev, R
    [J]. PEDIATRICS, 1998, 102 (03) : 538 - 545
  • [9] Incidence of invasive pneumococcal disease in children 3 to 36 months of age at a tertiary care pediatric center 2 years after licensure of the pneumococcal conjugate vaccine
    Lin, PL
    Michaels, MG
    Janosky, J
    Ortenzo, M
    Wald, ER
    Mason, E
    [J]. PEDIATRICS, 2003, 111 (04) : 896 - 899
  • [10] Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine
    Mbelle, N
    Heubner, RE
    Wasas, AD
    Kimura, A
    Chang, I
    Klugman, KP
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (04) : 1171 - 1176